| Company/Division name | Novartis |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2028 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 1100 |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | San Diego |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
